Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation

L. Buonaguro, M. L. Visciano, M. L. Tornesello, M. Tagliamonte, B. Biryahwaho, F. M. Buonaguro

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

We have recently developed a candidate human immunodeficiency virus type 1 (HIV-I) vaccine model, based on virus-like particles (VLPs) expressing gp120 from a Ugandan HIV-1 isolate of clade A (HIV-VLPAs), which shows the induction of neutralizing antibodies as well as cytotoxic T lymphocytes (CTL) in BALB/c mice by intraperitoneal (i.p.) administration. In the present study, immunization experiments based on a multiple-dose regimen have been performed with BALB/c mice to compare different routes of administration. i.p. and intranasal (i.n.), but not oral, administration induce systemic as well as mucosal (vaginal and intestinal) immunoglobulin G (IgG) and IgA responses. These immune sera exhibit >50% ex vivo neutralizing activity against both autologous and heterologous primary isolates. Furthermore, the administration of HIV-VLPAs by the i.n. immunization route induces a specific CTL activity, although at lower efficiency than the i.p. route. The HIV-VLP As represent an efficient strategy to stimulate both arms of immunity; furthermore, the induction of specific humoral immunity at mucosal sites, which nowadays represent the main port of entry for HIV-1 infection, is of great interest. All these properties, and the possible cross-clade in vivo protection, could make these HIV-VLPAs a good candidate for a mono- and multicomponent worldwide preventive vaccine approach not restricted to high-priority regions, such as sub-Saharan countries.

Original languageEnglish
Pages (from-to)7059-7067
Number of pages9
JournalJournal of Virology
Volume79
Issue number11
DOIs
Publication statusPublished - Jun 2005

Fingerprint

virus-like particles
Human immunodeficiency virus 1
Neutralizing Antibodies
neutralizing antibodies
Virion
HIV-1
cytotoxic T-lymphocytes
vaccination
HIV
mice
immunization
Cytotoxic T-Lymphocytes
vaccines
Immunization
Vaccines
immunoglobulin G
intraperitoneal injection
humoral immunity
neutralization
oral administration

ASJC Scopus subject areas

  • Immunology

Cite this

@article{8d9849e0e8d445ad99ada6590b0738c5,
title = "Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation",
abstract = "We have recently developed a candidate human immunodeficiency virus type 1 (HIV-I) vaccine model, based on virus-like particles (VLPs) expressing gp120 from a Ugandan HIV-1 isolate of clade A (HIV-VLPAs), which shows the induction of neutralizing antibodies as well as cytotoxic T lymphocytes (CTL) in BALB/c mice by intraperitoneal (i.p.) administration. In the present study, immunization experiments based on a multiple-dose regimen have been performed with BALB/c mice to compare different routes of administration. i.p. and intranasal (i.n.), but not oral, administration induce systemic as well as mucosal (vaginal and intestinal) immunoglobulin G (IgG) and IgA responses. These immune sera exhibit >50{\%} ex vivo neutralizing activity against both autologous and heterologous primary isolates. Furthermore, the administration of HIV-VLPAs by the i.n. immunization route induces a specific CTL activity, although at lower efficiency than the i.p. route. The HIV-VLP As represent an efficient strategy to stimulate both arms of immunity; furthermore, the induction of specific humoral immunity at mucosal sites, which nowadays represent the main port of entry for HIV-1 infection, is of great interest. All these properties, and the possible cross-clade in vivo protection, could make these HIV-VLPAs a good candidate for a mono- and multicomponent worldwide preventive vaccine approach not restricted to high-priority regions, such as sub-Saharan countries.",
author = "L. Buonaguro and Visciano, {M. L.} and Tornesello, {M. L.} and M. Tagliamonte and B. Biryahwaho and Buonaguro, {F. M.}",
year = "2005",
month = "6",
doi = "10.1128/JVI.79.11.7059-7067.2005",
language = "English",
volume = "79",
pages = "7059--7067",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation

AU - Buonaguro, L.

AU - Visciano, M. L.

AU - Tornesello, M. L.

AU - Tagliamonte, M.

AU - Biryahwaho, B.

AU - Buonaguro, F. M.

PY - 2005/6

Y1 - 2005/6

N2 - We have recently developed a candidate human immunodeficiency virus type 1 (HIV-I) vaccine model, based on virus-like particles (VLPs) expressing gp120 from a Ugandan HIV-1 isolate of clade A (HIV-VLPAs), which shows the induction of neutralizing antibodies as well as cytotoxic T lymphocytes (CTL) in BALB/c mice by intraperitoneal (i.p.) administration. In the present study, immunization experiments based on a multiple-dose regimen have been performed with BALB/c mice to compare different routes of administration. i.p. and intranasal (i.n.), but not oral, administration induce systemic as well as mucosal (vaginal and intestinal) immunoglobulin G (IgG) and IgA responses. These immune sera exhibit >50% ex vivo neutralizing activity against both autologous and heterologous primary isolates. Furthermore, the administration of HIV-VLPAs by the i.n. immunization route induces a specific CTL activity, although at lower efficiency than the i.p. route. The HIV-VLP As represent an efficient strategy to stimulate both arms of immunity; furthermore, the induction of specific humoral immunity at mucosal sites, which nowadays represent the main port of entry for HIV-1 infection, is of great interest. All these properties, and the possible cross-clade in vivo protection, could make these HIV-VLPAs a good candidate for a mono- and multicomponent worldwide preventive vaccine approach not restricted to high-priority regions, such as sub-Saharan countries.

AB - We have recently developed a candidate human immunodeficiency virus type 1 (HIV-I) vaccine model, based on virus-like particles (VLPs) expressing gp120 from a Ugandan HIV-1 isolate of clade A (HIV-VLPAs), which shows the induction of neutralizing antibodies as well as cytotoxic T lymphocytes (CTL) in BALB/c mice by intraperitoneal (i.p.) administration. In the present study, immunization experiments based on a multiple-dose regimen have been performed with BALB/c mice to compare different routes of administration. i.p. and intranasal (i.n.), but not oral, administration induce systemic as well as mucosal (vaginal and intestinal) immunoglobulin G (IgG) and IgA responses. These immune sera exhibit >50% ex vivo neutralizing activity against both autologous and heterologous primary isolates. Furthermore, the administration of HIV-VLPAs by the i.n. immunization route induces a specific CTL activity, although at lower efficiency than the i.p. route. The HIV-VLP As represent an efficient strategy to stimulate both arms of immunity; furthermore, the induction of specific humoral immunity at mucosal sites, which nowadays represent the main port of entry for HIV-1 infection, is of great interest. All these properties, and the possible cross-clade in vivo protection, could make these HIV-VLPAs a good candidate for a mono- and multicomponent worldwide preventive vaccine approach not restricted to high-priority regions, such as sub-Saharan countries.

UR - http://www.scopus.com/inward/record.url?scp=18744368156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744368156&partnerID=8YFLogxK

U2 - 10.1128/JVI.79.11.7059-7067.2005

DO - 10.1128/JVI.79.11.7059-7067.2005

M3 - Article

C2 - 15890945

AN - SCOPUS:18744368156

VL - 79

SP - 7059

EP - 7067

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 11

ER -